The insulin-like effect of vanadate on lipolysis in rat adipocytes is not accompanied by an insulin-like effect on tyrosine phosphorylation.
Tyrosine phosphorylation of the insulin receptor and other intracellular proteins in rat adipocytes was examined using an immunoblot technique with antiphosphotyrosine antibody. Insulin at 10(-7) M increased the tyrosine phosphorylation of the 95K subunit of the insulin receptor (15-fold) and proteins of 180K (7-fold) and 60K (23-fold). Increases in insulin-dependent phosphorylation of the three proteins were detectable at 10(-10) M insulin and attained steady state within 30 sec of insulin (10(-7) M) addition. Small effects of insulin (less than 30% increases) were observed on proteins of 120K and 53K. In contrast to insulin, the effects of vanadate on tyrosine phosphorylation were small and nonspecific. Vanadate increased tyrosine phosphorylation of the 95K insulin receptor beta-subunit and the 120K and 60K proteins similarly, with increases of 1.5- to 3-fold at 1 mM and 2-fold or less at 200 and 50 microM. Vanadate-dependent tyrosine phosphorylation of the 180K protein increased to a maximum of only 30% at 200 microM. Tyrosine phosphorylation of the 53K protein was somewhat larger, approaching 4-fold at 1 mM vanadate. The concentration of insulin and vanadate that inhibited isoproterenol-dependent lipolysis were not comparable to those that increased tyrosine phosphorylation. Vanadate at 1 mM was more potent as an antilipolytic agent than 10(-9) M insulin (93% vs. 81%), yet increased tyrosine phosphorylation of the 95K insulin receptor beta-subunit only as effectively as 10(-10) M insulin (which inhibited lipolysis only 42%). The dissimilar responses were even more pronounced when antilipolysis was compared to tyrosine phosphorylation of the 180K and 60K proteins. For example, insulin at 10(-9) M increased tyrosine phosphorylation of the 180K protein 2.9-fold, while 1 mM vanadate had a negligible effect (10% increase). Thus, vanadate exerts an insulin-like effect on lipolysis, yet its effects on tyrosine phosphorylation differ from those of insulin.
Mooney
R A
RA
Departments of Pathology and Laboratory Medicine, University of Rochester School of Medicine and Dentistry, New York 14642.
Bordwell
K L
KL
Luhowskyj
S
S
Casnellie
J E
JE
D000273:Adipose Tissue / Q000378:metabolism*; D000818:Animals; D015151:Immunoblotting; D007328:Insulin / Q000494:pharmacology*; D007545:Isoproterenol / Q000494:pharmacology; D008066:Lipolysis / Q000187:drug effects*; D008297:Male; D008970:Molecular Weight; D010750:Phosphoproteins / Q000378:metabolism*; D010766:Phosphorylation; D019000:Phosphotyrosine; D051381:Rats; D011919:Rats, Inbred Strains; D011972:Receptor, Insulin / Q000187:drug effects / Q000378:metabolism; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000378:metabolism; D014638:Vanadates / Q000494:pharmacology*
D007328:Insulin; D010750:Phosphoproteins; D019000:Phosphotyrosine; D014638:Vanadates; D014443:Tyrosine; D011972:Receptor, Insulin; D007545:Isoproterenol